{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:03Z","timestamp":1787163363761,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.adro.2023.101411","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T23:24:20Z","timestamp":1701818660000},"page":"101411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-9625","authenticated-orcid":false,"given":"Joyce H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana D.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gunasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Hammoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Anh","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica S.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"Balboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Hertan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2023.101411_bib0001","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Palliative radiotherapy trials for bone metastases: A systematic review","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0002","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","article-title":"Update on the systematic review of palliative radiotherapy trials for bone metastases","volume":"24","author":"Chow","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0003","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: A systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0005","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0007","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.adro.2023.101411_bib0008","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation versus stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0009","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2020.09.019","article-title":"CCTG SC.24\/TROG 17.06: A randomized phase II\/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases","volume":"108","author":"Sahgal","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: An open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0012","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","article-title":"Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy","volume":"128","author":"Sprave","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0013","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic versus conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: A randomized phase 2 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0014","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ijc.33744","article-title":"Pan-cancer analysis of prognostic metastatic phenotypes","volume":"150","author":"Zaorsky","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.adro.2023.101411_bib0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0016","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.09.008","article-title":"Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers","volume":"114","author":"Tsai","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0017","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0018","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijrobp.2020.11.060","article-title":"Pain response after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases\u2014a phase 2 randomized controlled trial within a prospective cohort","volume":"110","author":"Pielkenrood","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0020","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2013.50.1411","article-title":"Vertebral compression fracture after spine stereotactic body radiotherapy: A multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score","volume":"31","author":"Sahgal","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0021","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2021.7008","article-title":"Development and assessment of a predictive score for vertebral compression fracture after stereotactic body radiation therapy for spinal metastases","volume":"8","author":"Kowalchuk","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","article-title":"ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases","volume":"173","author":"van der Velden","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: An ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0024","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1200\/JCO.2008.17.1363","article-title":"Predictive model for survival in patients with advanced cancer","volume":"26","author":"Chow","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cncr.28408","article-title":"Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: The TEACHH model","volume":"120","author":"Krishnan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2023.101411_bib0026","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","article-title":"International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery","volume":"83","author":"Cox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0027","article-title":"Less time is less motion: Analysis of practical efficiencies gained with a modified workflow integrating planar kV midimaging with CBCT for spine stereotactic body radiation therapy","volume":"7","author":"Hu","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2022.06.096","article-title":"Patient and treatment factors associated with improved local control and survival in oligometastatic bone disease: Results from a large single-institution experience using stereotactic body radiation therapy","volume":"114","author":"Thomas","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0029","doi-asserted-by":"crossref","first-page":"E564","DOI":"10.1016\/j.ijrobp.2019.06.1219","article-title":"Intra-fraction motion of non-spine bone SBRT patients","volume":"105","author":"Bredfeldt","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0031","article-title":"Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for oligometastatic prostate cancer","volume":"7","author":"Brennan","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0032","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2008.02.060","article-title":"Stereotactic body radiosurgery for spinal metastases: A critical review","volume":"71","author":"Sahgal","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109792","article-title":"Predictors of pathologic fracture and local recurrence following stereotactic body radiation therapy to 505 non-spine bone metastases","volume":"186","author":"Nguyen","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0034","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2022.09.076","article-title":"Dose-escalated 2-fraction spine stereotactic body radiation therapy: 28 Gy versus 24 Gy in 2 daily fractions","volume":"115","author":"Zeng","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2023.101411_bib0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/neuros\/nyx493","article-title":"Vertebral compression fracture after spine stereotactic body radiation therapy: A review of the pathophysiology and risk factors","volume":"83","author":"Faruqi","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.adro.2023.101411_bib0036","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.prro.2013.05.006","article-title":"Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases","volume":"4","author":"Owen","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0037","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0038","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13014-018-1096-9","article-title":"A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)","volume":"13","author":"Mercier","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0039","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2023.101411_bib0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13046-018-0758-7","article-title":"Role of metabolism in cancer cell radioresistance and radiosensitization methods","volume":"37","author":"Tang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.adro.2023.101411_bib0041","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA\u2013PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.adro.2023.101411_bib0042","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.prro.2018.02.001","article-title":"Assessing the utility of the spinal instability neoplastic score (SINS) to predict fracture after conventional radiation therapy (RT) for spinal metastases","volume":"8","author":"Shi","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2023.101411_bib0043","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.adro.2023.101411_bib0044","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"Milano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2023.101411_bib0045","unstructured":"Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic (1-3 Metastases) cancer (SABR-COMET-3). ClinicalTrials.gov identifier: NCT03862911. Updated July 1, 2022. Accessed January 5, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03862911."},{"key":"10.1016\/j.adro.2023.101411_bib0046","unstructured":"Stereotactic ablative radiotherapy for comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET 10). ClinicalTrials.gov identifier: NCT03721341. Updated October 14, 2022. Accessed January 5, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03721341."}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109423002397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109423002397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:45:25Z","timestamp":1762530325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109423002397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2452109423002397"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2023.101411","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2023.101411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101411"}}